ROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
Wed, 03/11/2021 - 14:34
4 minROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
shutterstock_682694722.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 3 November 2021
In compliance with the reporting requirements provided for in article 226 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, Laboratorios Farmacéuticos ROVI, S.A. (hereon, “ROVI” or the “Company”) hereby discloses to the Spanish National Securities Market Commission the following
INSIDE INFORMATION
In accordance with the resolutions passed by the Board of Directors of the Company, under the authorization granted by the general shareholders’ meeting of the Company on 17 June 2021, item 13 of its agenda, it is hereby reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program (the “Buyback Program”) under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (“Regulation 596/2014”) and Commission Delegated Regulation (EU) No. 2016/1052 of 8 March 2016 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures (“Delegated Regulation 2016/1052”), in accordance with the following terms:
The Buyback Program shall be managed by Bestinver, S.V., S.A., that will manage the Buyback Program by making its decisions regarding the implementation of the purchases of ROVI’s shares and their price and volume conditions independently. Any potential amendment, interruption or termination of the Buyback Program and any acquisition of shares thereunder shall be communicated to the Spanish National Securities Market Commission pursuant to article 5 of Regulation 595/2014 and Delegated Regulation 2016/1052. During the term of the Buyback Program the transactions regulated under the liquidity agreement entered into between ROVI and Renta 4 Banco, S.A. on 8 May 2019 will be suspended, in accordance with Circular 1/2017 of 26 April, of the Spanish National Securities Market Commission, pursuant to the provisions of rule 5, section c). The aforementioned transactions will resume once the Buyback Program ends.
In Madrid, 3 November 2021
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.